Phosphodiesterase Inhibition As A Chemotherapeutic Adjuvant For Prostate Cancer
September 26th, 2008 by allsoch
ORLANDO, FL (UroToday.com) - Low tumor oxygenation (hypoxia) correlates with resistance to chemotherapeutic agents. A group of Canadian investigators have recently demonstrated that in vitro and in vivo hypoxia-inducedresistance to various anti-cancer drugs can be attenuated by manipulating nitric oxide (NO) signaling through cGMP mediated pathways. The aim of this study was to determine whether PDE inhibitors are able to inhibit hypoxia-induced chemoresistance in prostate carcinoma cells.
Posted in Uncategorized | No Comments »
ORLANDO, FL (UroToday.com) - Pathology results after partial nephrectomy reveal a positive margin. What should the urologist tell the patient? Is immediate reoperation warranted? Patard and colleagues addressed these questions by examining data from a large international multi-institution surgical series that included 811 patients who underwent partial nephrectomy (PN) for tumors with a mean size of 3cm (0.5-16). 40% of operations were performed for imperative indications, while 60% of PNs were elective. 119 (14.7%) specimens contained a positive margin (PSM), and all patients were managed expectantly. The authors did two separate comparative analyses using the data. They first contrasted the PSM patients with the rest of the cohort. Then they compared the 109 PSM patients to the 108 controls that were closely match by indication for surgery, tumor size, and Fuhrman grade.
ORLANDO, FL (UroToday.com) - Dr. Lim presented a study attempting to identify factors that predict post-operative deterioration to stage 4 chronic renal disease (GFR <25ml/min) in patients undergoing radical (RN) or partial nephrectomies (PN) from the University of Western Ontario.
Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) will be presenting its lead cancer technology at this prestigious symposium in Geneva Switzerland in October 2008. Targeted initially for brain tumors, this technology is a major breakthrough in inhibiting glycolysis, a process many tumor cells, but not normal cells, require for growth and survival. Inhibition of glycolysis “starves” tumors by blocking their ability to provide the energy needed for survival. The founding scientists have designed a drug that passes through the Blood Brain Barrier (BBB), a protective tissue which prevents most other drugs from entering the brain, where this drug is then retained in brain tumor cells selectively blocking the tumors metabolic machinery. This technology is also applicable to other cancers that are depend on glycolysis for survival such as breast and pancreatic cancers. This technology is covered under Oncolin’s recent exclusive option to license from The University of Texas M.D. Anderson Cancer Center, the # 1 cancer treatment center in the United State according to U.S. News and World Report.
ORLANDO, FL (UroToday.com) - A Swiss group sought to determine if a prognostic difference exists between primary and initially superficial but subsequently progressive invasive pathological pT3a and b transitional cell carcinoma (TCC) of the bladder.
ORLANDO, FL (UroToday.com) - Previous studies have suggested that prostate cancer in young men may behave more aggressively. These reports have recently been refuted. There remains a scarcity of data on the biochemical outcome after radical prostatectomy specifically for men in their 30’s.
Australia’s Victorian Premier John Brumby has announced a $100 million (AUD) initiative to build the world’s largest life sciences supercomputer facility to assist in discovering cures and therapies for such life-threatening diseases such as cancer, brain disorders and ‘flu pandemics.
ORLANDO, FL (UroToday.com) - The ratio of Matrix metalloproteinase to E-cadherin (M/E ratio) characterizes the “invasive profile” of prostate cancer. In the present study a group of researchers from Houston performed a comparative analysis of the M/E ratio among Caucasian (CAU) and African- American (AA) patients undergoing radical prostatectomy (RP).
According to a survey released today by C-Change, a national cancer coalition of key leaders from the government, business and non-profit sectors, Americans are not aware of the important role they play in cancer prevention. Conducted in January 2008, the survey focused on American attitudes and behaviors about cancer prevention and found that:
ORLANDO, FL (UroToday.com) - Crispen and colleagues examined growth pattern kinetics in their series of renal masses under surveillance. This report describes 161 lesions in 146 patients with a median follow up of 26 months (12 - 156 months). The tumors in the series had the following characteristics: median diameter 2.0 cm (0.4 to 12.0 cm), median volume 4.18cm3 (0.0033 - 903.74 cm3). 85% of the lesions were solid on imaging at presentation.